AstraZeneca wiped £19bn from its value in a day — what happened and what’s next for the stock?

AstraZeneca is one of the most widely held stocks in UK pension funds and ISAs — so when its shares fall 9.55% in a single day, it matters for millions of British investors. The cause was a surprise: Wainua, a gene-silencing heart drug developed with US partner Ionis Pharmaceuticals, failed a pivotal Phase III clinical trial on 9 July 2026. The news wiped approximately £19 billion from AstraZeneca’s market value and made it the worst performer on the FTSE 100 by some distance (Proactive Investors, 9 July 2026).

The failure was unexpected. This was not a drug that analysts had marked as high-risk — it had shown positive signals in earlier stages and was being developed in a disease area with validated competitive drugs already on the market. Here’s what happened, what it means for AstraZeneca’s pipeline, and how investors should think about a single trial failure in a large pharmaceutical company.

What is Wainua and what was it being tested for?

Wainua (generic name: eplontersen) is a gene-silencing medicine that works by reducing the production of a protein called transthyretin (TTR). In its approved form, it is used to treat hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) — a progressive nerve-damage condition caused by misfolded TTR protein accumulating in the body. It is already approved in more than 20 countries for this indication and is sold in Europe as Wainzua.

The CARDIO-TTRansform trial was testing Wainua in a different but related condition: transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). In ATTR-CM, misfolded TTR protein accumulates in the heart muscle rather than the nerves, stiffening it and progressively impairing the heart’s ability to pump blood. The condition affects an estimated 300,000 to 500,000 people globally and has historically been underdiagnosed (Reuters / CNBC, 9 July 2026).

ATTR-CM is a commercially significant target. Pfizer’s Vyndamax has long been the dominant drug in the indication; in recent years it has been joined by BridgeBio’s stabiliser drug and Alnylam’s Amvuttra — a silencer drug using a similar mechanism to Wainua. Analysts had estimated Wainua could capture $2 billion in peak annual sales in this indication (Reuters, 9 July 2026).

What did the trial show?

The CARDIO-TTRansform trial enrolled 1,432 patients across 130 sites in 20 countries — the largest ever trial in ATTR-CM — and followed participants over 140 weeks. The primary endpoint was a composite of cardiovascular deaths and recurrent cardiovascular events (Reuters, 9 July 2026).

Wainua did not meet that primary endpoint compared to placebo. AstraZeneca said the drug showed “no statistically significant benefit” overall. The company noted a pre-specified subgroup of patients receiving Wainua without a stabiliser drug showed nominally significant benefit — but no treatment effect was seen in the larger group of patients already on stabiliser therapy, which comprised the majority of participants (MedCity News, 9 July 2026).

Ionis management, in an analyst call, confirmed that no benefit was shown overall and that the company does not believe a longer trial would have produced a different outcome. Full data will be presented at the European Society of Cardiology Congress in August 2026.

The CARDIO-TTRansform trial was the largest ever run in ATTR-CM, with 1,432 patients across 130 sites in 20 countries. It followed patients for 140 weeks — almost three years. The scale of the miss and the inability of a longer study to change the outcome are what make this a definitive failure rather than an inconclusive result. (MedCity News / Ionis, 9 July 2026)

Why was the failure a surprise?

Trial failures are common in pharmaceutical development — most drug candidates never reach approval. What made this one notable is that Wainua was not considered high-risk by the investment community.

Bank of America analysts stated bluntly: “Data comes as a surprise given we and investors hadn’t even debated likelihood of a primary endpoint miss, given positive precedent data and successful launch for competitor Amvuttra” (Reuters, 9 July 2026). Alnylam’s Amvuttra uses a similar gene-silencing mechanism and had succeeded in ATTR-CM — providing what appeared to be clinical validation for the approach.

The most likely explanation for the divergence is trial design: the CARDIO-TTRansform trial included a large proportion of patients already receiving stabiliser drugs (primarily Pfizer’s Vyndamax or BridgeBio’s drug). In that subgroup, adding Wainua provided no additional benefit — suggesting that once a stabiliser is already working, a silencer cannot add meaningfully on top. Alnylam’s successful Amvuttra trial used a different patient population with less stabiliser background therapy (MedCity News, 9 July 2026).

What does it mean for AstraZeneca’s £80bn target?

AstraZeneca has set a target of $80 billion in annual revenue by 2030, up from approximately $54 billion in 2025. Reaching that target requires a combination of existing blockbusters, line extensions, and new approvals — with up to 20 new drug launches planned.

Wainua in ATTR-CM was expected to be one of those contributors, with $2 billion in peak sales at stake. Its failure removes that contribution from the pipeline model and raises questions about the company’s cardiovascular ambitions following another setback in May 2026, when a US regulatory panel rejected breast cancer drug camizestrant on trial design grounds (Reuters, 9 July 2026).

However, analysts are not uniformly negative. Citi has consistently described AstraZeneca as having “the best growth and best pipeline in European pharma”, with $46 billion in risk-adjusted peak pipeline sales and ten further Phase III readouts due in 2026 (Proactive Investors, 9 July 2026). The existing Wainua approval for ATTR polyneuropathy is unaffected and continues to generate revenue. A single trial failure, while painful, does not define the entire pipeline.

Who benefits from the trial failure?

AstraZeneca’s loss is Alnylam’s gain. With Wainua now out of the ATTR-CM silencer market, Alnylam’s Amvuttra becomes the only gene-silencing drug approved for the indication — removing its principal competitive threat and giving it a monopoly in that mechanism category (CNBC, 9 July 2026).

Alnylam and BridgeBio shares climbed 11–16% on the news (CNBC, 9 July 2026). Ionis Pharmaceuticals — AstraZeneca’s partner in the trial — fell 13.8–19% in pre-market trading, compounding a difficult year for the company.

How should investors think about pipeline setbacks?

Clinical trial failures are an inherent part of pharmaceutical investing. The industry rule of thumb is that approximately 90% of drug candidates that enter clinical trials never reach approval — Phase III failures, which are the most costly, occur in roughly 40–50% of late-stage programmes across the industry.

For a company the size of AstraZeneca, with revenues of $54 billion and a pipeline of dozens of programmes, a single Phase III failure is a setback but not a structural crisis. What matters for long-term investors is the breadth and quality of the overall pipeline rather than any single trial outcome.

That said, the Wainua failure is AstraZeneca’s second high-profile setback in two months. Two failures in quick succession can affect management credibility and pipeline confidence ratings even when the underlying portfolio remains strong. This is not personalised financial advice — investors should consider their own circumstances and risk appetite.

AstraZeneca trial failure summed up

• Wainua failed the Phase III CARDIO-TTRansform trial in ATTR-CM on 9 July 2026 — a surprise miss that wiped £19bn from AstraZeneca’s market value
• Shares fell 9.55% — AstraZeneca’s worst single day since March 2020 (Reuters, 9 July 2026)
• The failure dims $2bn peak sales estimates for Wainua in ATTR-CM; the existing nerve-damage approval is unaffected
• The likely cause: high stabiliser drug background therapy in the trial population, which masked any Wainua effect
• Alnylam and BridgeBio gained 11–16%; Alnylam’s Amvuttra is now the only gene-silencing drug in ATTR-CM
• Citi still rates AstraZeneca as best pipeline in European pharma; 10 further Phase III readouts due in 2026
• Past performance is not a reliable indicator of future results. Capital at risk.

Frequently asked questions

Past performance is not a reliable indicator of future results.